Jeddah, Saudi Arabia — Alpha Pharma, a leading Saudi pharmaceutical company and manufacturer of specialty generics and innovative pharmaceutical products, today announced the signing of a Memorandum of Understanding with Biotest AG for Alpha Pharma's private label of the plasma derivatives products for the KSA market.
The company makes this strategic step in alignment with the Saudi Vision 2030 and follows His Royal Highness Crown Prince and Prime Minister Mohamed Bin Salman on supporting the national security of medicines and encouraging the local manufacturers to localize the manufacturing of critical medicines to fulfill/address country's increasing healthcare needs.
Alpha Pharma to become the first Saudi manufacturer to enter the field of plasma products in KSA and the GCC region. The company has recognized the significant potential and effectiveness of plasma-based treatments for patients suffering from various immune or blood illnesses and it aspires to be the leading producer and provider of innovative plasma-based therapies in the region.
“I am proud to see Alpha Pharma establishing strategic partnership with Biotest AG and creating the unique opportunity of being the first Saudi producer of plasma- based innovative therapies for patients in Saudi and other countries across the GCC region.” - said Shaikh Yaser Al Naghi, Chairman of Alpha Pharma and Group CEO of Cigalah Healthcare.
“Today marks a very important moment for Alpha Pharma, and we are looking forward to collaborating with Biotest AG on bringing first plasma derivatives product solutions to our region” – added Dr. Murad Al Saggaf, General Manager of Alpha Pharma.
"We are very excited to form part of this strategic collaboration which will contribute to the development of the Saudi Arabian health system and will allow more people to have access to our treatments,” - said Dr Enrico D'Aiuto, Senior Vice President Commercials Operation of Biotest.
Until the new infrastructure is operative, Biotest AG will continue to guarantee the supply of plasma-derived products to Saudi Arabia through the supply and distribution agreement with Cigalah Healthcare.
Biotest AG will provide the knowledge and technical expertise and will also supply plasma medicines through to Saudi Arabia until Alpha Pharma becomes capable of producing them.
Until the new infrastructure is operative, Biotest AG will continue to guarantee the supply of plasma-derived products to Saudi Arabia through the supply and distribution agreement with Cigalah Healthcare.
Biotest AG will provide the knowledge and technical expertise and will also supply plasma medicines through to Saudi Arabia until Alpha Pharma becomes capable of producing them.
Biotest AG and Alpha Pharma are establishing a new way of partnership with a stepwise approach that includes localization steps in the country, self-sufficiency for plasma proteins products in the Saudi market, and increasing access to therapies for Saudi Arabia patients.
Facebook Conversations
Disqus Conversations